{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=33", "query": { "intervention": "VEGF", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 829, "total_pages": 83, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VEGF&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T18:01:18.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00936936", "title": "High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Testicular Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2009-06-02", "completion_date": "2024-01-11", "has_results": true, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00936936" }, { "nct_id": "NCT00428545", "title": "Bevacizumab and Bortezomib in Patients With Advanced Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Lymphoma", "Myeloma", "Solid Tumors" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 104, "start_date": "2007-01", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428545" }, { "nct_id": "NCT00028834", "title": "Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028834" }, { "nct_id": "NCT07159828", "title": "A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "AXN-2510", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Axion Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2025-09-15", "completion_date": "2026-04-16", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 7, "location_summary": "Huntersville, North Carolina • Dallas, Texas • Houston, Texas + 2 more", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07159828" }, { "nct_id": "NCT01136967", "title": "An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Stage III", "Stage IV Melanoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 182, "start_date": "2010-08", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 79, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01136967" }, { "nct_id": "NCT06449209", "title": "Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer", "Small-cell Lung Cancer" ], "interventions": [ { "name": "BNT327 Dose Level 1 (DL1)", "type": "DRUG" }, { "name": "BNT327 Dose Level 2 (DL2)", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2024-08-05", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 18, "location_summary": "Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Angeles", "state": "California" }, { "city": "Clermont", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06449209" }, { "nct_id": "NCT05610319", "title": "Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "McMaster University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2023-05-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 11, "location_summary": "Modesto, California • Sacramento, California • Oak Forest, Illinois + 7 more", "locations": [ { "city": "Modesto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Oak Forest", "state": "Illinois" }, { "city": "West Monroe", "state": "Louisiana" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT05610319" }, { "nct_id": "NCT02974621", "title": "Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-12-07", "completion_date": "2027-07-17", "has_results": true, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 27, "location_summary": "La Jolla, California • Aurora, Colorado • Derby, Connecticut + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974621" }, { "nct_id": "NCT01157065", "title": "Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age-Related Macular Degeneration" ], "interventions": [ { "name": "AL-78898A", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 99, "start_date": "2011-06", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01157065" }, { "nct_id": "NCT04476329", "title": "Optimization for Regorafenib in HCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Regorafenib 40 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SC Liver Research Consortium, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-01-21", "completion_date": "2021-12-10", "has_results": false, "last_update_posted_date": "2021-12-30", "last_synced_at": "2026-11-03T18:01:18.277Z", "location_count": 9, "location_summary": "Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04476329" } ] }